Wall Street will be watching when cancer specialists from around the world gather in Chicago June 1 to 5 for the annual meeting of The American Society of Clinical Oncology. Investors take keen interest in the ASCO proceedings in hopes of gaining insight into which cancer therapies moving through clinical trials will be successful. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about ASCO, what the already-released abstracts are telling us, and what companies to watch as the meeting gets underway. Read More
Finance
- Paying for Value
Drugmakers challenged to provide adequate data as payers move to reimburse for outcomes rather than drugs. Read More
Comparative Effectiveness
- PCORI Aims to Award $120 Million in 2012
Funding will support comparative clinical effectiveness research. Read More
Diabetes
- Death Rates among Americans with Diabetes Falls
Despite improvement, disease expected to afflict a greater proportion of people in the United States. Read More
Mergers and Acquisitions
- GSK Responds to Human Genome’s Poison Pill
To avoid dilution, HGS buyers would need board’s blessing. Read More
Digital Health
- Homeland Security Warns of Mobile Health Risks
Increasing use of wireless technologies comes with increased threat to network security. Read More
Trials and Tribulations
- Teva Cuts Forecasts over European Weakness
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
Markets
- U.S. Could Lose its Competitive Edge in Biomedical Innovation
Two reports highlight challenges to U.S. leadership position. Read More
Deals
- Public Private Partnership Aims to Combat Drug Resistant Microbes
Pharmaceutical companies join forces with European initiative to speed development of new antibiotics. Read More
Global Health
- NIH Study Shows Fake and Poor Quality Malaria Drugs Pose Threat
Progress against the disease is hampered by growing array of problems. Read More
Regenerative Medicine / Stem Cells
- Osiris Wins Canadian Approval for World’s First Stem Cell Drug
Prochymal is only approved treatment for GvHD. Read More
- The Burrill Report (May 29, 2012): Wall Street Turns Its Eyes to ASCO
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
June 2012
Download a free copy of the June 2012 issue of The Burrill Report. Focus on Dealmaking
Diane Mulcahy, director of private equity for the Kauffman Foundation, disccuses her organization's report that discusses the failings of investors in venture capital funds venture capital funds, why venture funds and their limited partners interests are often misaligned, and what needs to be done to fix the problem.
Finance Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
Five European pharmaceutical companies are teaming up with leading academics as part of the Innovative Medicines Initiative to combat antimicrobial resistance and speed up research for new antibiotics.
.jpg)
.gif)
.png){kind=small} |
 |